超滤装置选择影响危重症患者β-内酰胺类抗生素游离浓度测定
该研究在磷酸盐缓冲液、加标血浆及危重症患者血浆中比较Centrifree与Amicon两种超滤装置对头孢吡肟、美罗培南、氟氯西林、哌拉西林和他唑巴坦游离浓度的测定。Centrifree对上述抗生素无显著非特异性结合(≤15%),而Amicon对美罗培南、氟氯西林和哌拉西林存在显著非特异性结合,导致测得的游离浓度偏低。
要点
- Centrifree对五种抗生素的非特异性结合均≤15%,未显示显著吸附。
- Amicon对美罗培南、氟氯西林和哌拉西林有显著非特异性结合,使游离浓度被低估。
- 哌拉西林(及较少程度氟氯西林)在Amicon中呈浓度依赖性非特异性结合。
核心结论
- 不同超滤装置测定的β-内酰胺类抗生素游离浓度存在显著差异,该差异与药物种类及非特异性结合有关。
- 开发游离浓度测定方法时应考虑超滤装置带来的非特异性结合影响。
研究设计与样本
- 在磷酸盐缓冲液中评估非特异性结合,并在加标血浆和危重症患者血浆中用色谱法测定游离浓度,比较Centrifree与Amicon两种超滤装置。
主要发现
- Centrifree对头孢吡肟、美罗培南、氟氯西林、哌拉西林和他唑巴坦的非特异性结合均≤15%。
- Amicon对美罗培南的非特异性结合为26-61%,对氟氯西林为18-58%,对哌拉西林为15-72%。
- ICU患者中游离分数(均值±标准差):头孢吡肟Centrifree 0.85±0.12 vs Amicon 0.90±0.10;美罗培南0.87±0.07 vs 0.77±0.05;氟氯西林0.25±0.13 vs 0.18±0.13;哌拉西林0.91±0.07 vs 0.67±0.13;他唑巴坦0.97±0.08 vs 0.95±0.08。
- 哌拉西林及较少程度的氟氯西林在Amicon中表现出浓度依赖性非特异性结合。
临床怎么用
- 危重症患者β-内酰胺类抗生素游离浓度监测或药代动力学研究应优先选用非特异性结合低的超滤装置(如Centrifree)。
- 若使用Amicon等存在非特异性结合的装置,需对美罗培南、氟氯西林和哌拉西林的游离浓度结果进行校正或谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Therapeutic drug monitoring (TDM) and pharmacokinetic studies of beta-lactam antibiotics in critically ill patients aim to define optimal dosing and require accurate measurement of unbound drug concentrations. This study compared the performance of two ultrafiltration devices, Centrifree and Amicon, for measuring unbound concentrations of cefepime, meropenem, flucloxacillin, piperacillin and tazobactam. METHODS: Non-specific binding (NSB) was specifically assessed in phosphate-buffered saline, and unbound concentrations were measured using a chromatographic method in both spiked plasma and plasma samples from critically ill patients, in order to compare the two ultrafiltration devices. RESULTS: Centrifree exhibited no significant NSB for any antibiotics (≤ 15%), while Amicon displayed significant NSB for meropenem (26-61%), flucloxacillin (18-58%) and piperacillin (15-72%), resulting in lower unbound concentrations in both patient and spiked plasma samples compared to Centrifree. Additionally, piperacillin, and to a lesser extent flucloxacillin, demonstrated concentration-dependent NSB with Amicon. The comparative mean ± standard deviation of unbound fractions in intensive care unit (ICU) patients were as follows: cefepime, 0.85 ± 0.12 (Centrifree) versus 0.90 ± 0.10 (Amicon); meropenem, 0.87 ± 0.07 (Centrifree) versus 0.77 ± 0.05 (Amicon); flucloxacillin, 0.25 ± 0.13 (Centrifree) versus 0.18 ± 0.13 (Amicon); piperacillin, 0.91 ± 0.07 (Centrifree) versus 0.67 ± 0.13 (Amicon); and tazobactam, 0.97 ± 0.08 (Centrifree) versus 0.95 ± 0.08 (Amicon). CONCLUSION: These findings underscore significant differences in results between ultrafiltration devices, depending on the drug, influenced by NSB. Such factors should be considered when developing methods for determining unbound concentrations of beta-lactam antibiotics.
引用
- Gregoire M, Wallis SC, Williams PG, et al. Protein Binding Determination of Cefepime, Flucloxacillin, Meropenem, Piperacillin and Tazobactam by Ultrafiltration in Critically Ill Patients: The Choice of Device Matters. Clin Pharmacokinet. 2026. PMID: 42667589. doi:10.1007/s40262-026-01659-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。